Pharmacokinetics and pharmacodynamics of hyaluronan infused into healthy human volunteers

Open Drug Metabolism Journal

Volumn 3, Issue , 2009, Pages 43-55

  Hamilton, Sara Rae ^a,b   Veiseh, Mandana ^c   Tölg, Cornelia ^a   Tirona, Rommel ^d   Richardson, Jakob ^a   Brown, Richard ^e   Gonzalez, Mario ^f   Vanzieleghem, Michael ^g   Anderson, Patricia ^h   Asculai, Samuel ⁱ   Winnik, Françoise ^j   Savani, Rashmin ^k,l   Freeman, David ^b   Luyt, Leonard ^b   Koropatnick, James ^a,b   Turley, Eva Ann ^a,b  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d WESTERN UNIVERSITY   (Canada)

^e BioMS Medical Corp   (Canada)

^f P kinetics Corp   (United States)

^g MV Pharmaceutical Consultants   (Canada)

^h CanReg Inc   (Canada)

ⁱ Bio Strategies Consulting Group   (Canada)

^j BOMBARDIER AEROSPACE   (Canada)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; HYALURONIC ACID;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MONOCYTE; NONLINEAR SYSTEM; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RASH; UNSPECIFIED SIDE EFFECT; VOLUNTEER;

EID: 77953379629     PISSN: None     EISSN: 18740731     Source Type: Journal    
DOI: 10.2174/1874073100903010043     Document Type: Article

References (59)

1. Tammi, M.I.; Day, A.J.; Turley, E.A. Hyaluronan and homeostasis: a balancing act. J. Biol. Chem., 2002, 277(7), 4581-4584.
2. Toole, B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer, 2004, 4(7), 528-539
3. Laurent, T.C.; Fraser, J.R. Hyaluronan. FASEB J., 1992, 6(7), 2397-2404.
4. Jiang, D.; Liang, J.; Noble, P.W. Hyaluronan in tissue injury and repair. Annu. Rev. Cell Dev. Biol., 2007, 23, 435-461
5. Itano, N. Simple primary structure, complex turnover regulation and multiple roles of hyaluronan. J. Biochem., 2008, 144(2), 131-137.
6. Fraser, J.R.; Laurent, T.C. Turnover and metabolism of hyaluronan. Ciba Found Symp., 1989, 143, 41-53; discussion 53-9, 281-285.
7. Toole, B.P.; Slomiany, M.G. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin. Cancer Biol., 2008, 18(4), 244-250.
8. Friedman, P.M.; Mafong, E.A.; Kauvar, A.N.; Geronemus, R.G. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol. Surg., 2002, 28(6), 491-494.
9. Geier, K.A.; Keeperman, J.B.; Sproul, R.C.; Roth, K.; Reynolds, H.M. Viscosupplementation: a new treatment option for osteoarthritis. Orthop. Nurs., 2002, 21(5), 25-32.
10. Itokazu, M.; Matsunaga, T. Clinical evaluation of high-molecular-weight sodium hyaluronate for the treatment of patients with periarthritis of the shoulder. Clin. Ther., 1995, 17(5), 946-955.
11. Turley, E.A.; Noble, P.W.; Bourguignon, L.Y. Signaling properties of hyaluronan receptors. J. Biol. Chem., 2002, 277(7), 4589-4592.
12. Slevin, M.; Kumar, S.; Gaffney, J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J. Biol. Chem., 2002, 277(43), 41046-41059 (Pubitemid 35215695)
13. Jackson, D.G. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc. Med., 2003, 13(1), 1-7.
14. Weigel, P.H.; Yik, J.H. Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. Biochim. Biophys. Acta, 2002, 1572(2-3), 341-363.
15. Stern, R. Hyaluronidases in cancer biology. Semin. Cancer Biol., 2008, 18(4), 275-280.
16. Lokeshwar, V.B.; Selzer, M.G. Hyalurondiase: both a tumor promoter and suppressor. Semin. Cancer Biol., 2008, 18(4), 281-287
17. Abate, M.; Pelotti, P.; De Amicis, D.; Di Iorio, A.; Galletti, S.; Salini, V. Viscosupplementation with hyaluronic acid in hip osteoarthritis (a review). Ups J. Med. Sci., 2008, 113(3), 261-277.
18. Cohen, J.L. Understanding, avoiding, and managing dermal filler complications. Dermatol. Surg., 2008, 34(Suppl 1), S92-9.
19. Hunter, D.J.; Hellio Le Graverand-Gastineau, M.P. How close are we to having structure-modifying drugs available? Med. Clin. North Am., 2009, 93(1), 223-234.
20. Maria, B.L.; Gupta, N.; Gilg, A.G.; Abdel-Wahab, M.; Leonard, A.P.; Slomiany, M.; Wheeler, W.G.; Tolliver, L.B.; Babcock, M.A.; Lucas, J.T. Jr.; Toole, B.P. Targeting hyaluronan interactions in spinal cord astrocytomas and diffuse pontine gliomas. J. Child. Neurol., 2008, 23(10), 1214-1220.
21. Eliaz, R.E.; Szoka, F.C. Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res., 2001, 61(6), 2592-2601.
22. Ruponen, M.; Ronkko, S.; Honkakoski, P.; Pelkonen, J.; Tammi, M.; Urtti, A. Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes. J. Biol. Chem., 2001, 276(36), 33875-33880. (Pubitemid 37384611)
23. Luo, Y.; Ziebell, M.R.; Prestwich, G.D. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules, 2000, 1(2), 208-218
24. Vignal, P.; Meslet, M.R.; Romeo, J.M.; Feuilhade, F. Sonographic morphology of infiltrating breast carcinoma: relationship with the shape of the hyaluronan extracellular matrix. J. Ultrasound Med., 2002, 21(5), 532-538. (Pubitemid 34457348)
25. Gouin, S.; Winnik, F.M. Quantitative assays of the amount of diethylenetriaminepentaacetic acid conjugated to water-soluble polymers using isothermal titration calorimetry and colorimetry. Bioconjug. Chem., 2001, 12(3), 372-377.
26. Lindqvist, U. Is serum hyaluronan a helpful tool in the management of patients with liver diseases? J. Intern. Med., 1997, 242(1), 67-71. (Pubitemid 27323868)
27. Lindqvist, U.; Groth, T.; Lebel, L. Evaluation of various models of hyaluronan kinetics for assessment of liver function. Scand. J. Clin. Lab. Invest., 1997, 57(1), 49-58. (Pubitemid 27160885)
28. Lebel, L.; Gabrielsson, J.; Laurent, T.C.; Gerdin, B. Kinetics of circulating hyaluronan in humans. 4. Eur. J. Clin. Invest., 1994, 24(9), 621-626.
29. Shah, B.; Sucher, K.; Hollenbeck. C.B. Comparison of ideal body weight equations and published. Nutr. Clin. Pract., 2006, 21(3), 312-319.
30. Pledger, G. Proof of efficacy trials: choosing the dose. Epilepsy Res., 2001, 45(1-3), 23-28 (Pubitemid 32673582)
31. Suri, A.; Estes, K.S.; Geisslinger, G.; Derendorf, H. Pharmacokinetic-pharmacodynamic relationships for analgesics. Int. J. Clin. Pharmacol. Ther., 1999, 35(8), 307-323. (Pubitemid 27354908)
32. st WMA General Assembly: Hong Kong, 1989.
33. Masellis-Smith, A.; Belch, A.R.; Mant, M.J.; Turley, E.A.; Pilarski L.M. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44. Blood, 1996, 87(5), 1891-1899. (Pubitemid 26068905)
34. Filion, M.C.; Phillips, N.C. Pro-inflammatory activity of contaminating DNA in hyaluronic acid preparations. J. Pharm. Pharmacol., 2001, 53(4), 555-561.
35. Hjerpe, A.; Antonopoulos, C.A.; Engfeldt, B.; Wilstrom, B. Analysis of dentine glycosaminoglycans using high-performance liquid chromatography. Calcif Tissue Int., 1983, 35(4-5), 496-501.
36. Somani, B.L.; Khanade, J.; Sinha, R. A modified anthrone-sulfuric acid method for the determination of fructose in the presence of certain proteins. Anal. Biochem., 1987, 167(2), 327-330. (Pubitemid 18022946)
37. Thompson, G.A.; Shumaker, R.C. MLTIDOSE: a multiple-dose simulation program for linear systems characterized by exponential functions. Drug Metab. Rev., 1989, 21(3), 463-469.
38. Lindqvist, U.; Groth, T.; Loof, L.; Hellsing, K. A hyaluronan-loading test applied to patients with liver and joint diseases. Clin. Chim. Acta, 1992, 210(1-2), 119-132
39. Maxwell, C.A.; McCarthy, J.; Turley, E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J. Cell Sci., 2008, 121(Pt 7), 925-932.
40. Salisbury, B.G.; Wagner, W.D. Isolation and preliminary characterization of proteoglycans dissociatively extracted from human aorta. J. Biol. Chem., 1981, 256(15), 8050-8057.
41. Schmidt, A.; von Teutul, A.; Buddecke, E. Characterization of proteoglycans synthesized by cultured arterial smooth muscle cells of the rat. Hoppe Seylers Z Physiol. Chem., 1984, 365(4), 445-456. (Pubitemid 14113928)
42. Rogers, H.J. Very high molecular weight mucopolysaccharides and mucopolysaccharide-protein complexes - how far can we extrapolate? Fed. Proc., 1966, 25(3),1035-1036.
43. Balazs, E.A.; Bland, P.A.; Denlinger, J.L.; Goldman, A.I.; Larsen, N.E.; Leschiner, E.A.; Leschiner, A.; Morales, B. Matrix engineering. Blood Coagul. Fibrinolysis, 1991, 2(1), 173-178.
44. Rosier, R.N.; O'Keefe, R.J. Hyaluronic acid therapy. Instr. Course Lect., 2000, 49, 495-502.
45. Jarvis, B.; Figgitt, R.J. Topical 3% diclofenac in 2.5% hyaluronic acid gel: a review of its use in patients with actinic keratoses. Am. J. Clin. Dermatol., 2003, 4(3), 203-213.
46. Espallargues, M.; Pons, J.M. Efficacy and safety of viscosupplementation with Hylan G-F 20 for the treatment of knee osteoarthritis: a systematic review. Int. J. Technol. Assess Health Care, 2003, 19(1), 41-56. (Pubitemid 36356326)
47. Balazs, E.A. Analgesic effect of elastoviscous hyaluronan solutions and the treatment of arthritic pain. Cells Tissues Organs, 2003, 174(1-2), 49-62.
48. Lane, S.S.; Lindstrom, R.L. Viscoelastic agents: formulation, clinical applications, and complications. Semin. Ophthalmol., 1992, 7(4), 253-260.
49. Liesegang, T.J. Viscoelastic substances in ophthalmology. Surv. Ophthalmol., 1990, 34(4), 268-293.
50. Pavesio, A.; Renier, D.; Cassinelli, C.; Morra, M. Anti-adhesive surfaces through hyaluronan coatings. Med. Device Technol., 1997, 8(7), 24-27.
51. Cera, C.; Plumbo, M.; Stefanelli, S.; Rassu, M.; Palu, G. Watersoluble polysaccharide-anthracycline conjugates: biological activity. Anticancer Drug Des., 1992, 7(2), 143-151.
52. Thierry, B.; Winnik, F.M.; Merhi, Y.; Silver, J.; Tabrizian, M. Radionuclides-hyaluronan-conjugate thromboresistant coatings to prevent in-stent restenosis. Biomaterials, 2004, 25(17), 3895-3905. (Pubitemid 38327079)
53. Heublein, B.; Evagorou, E.G.; Rohde, R.; Ohse, S.; Meliss, R.R.; Barlach, S.; Haverich A. Polymerized degradable hyaluronan - a platform for stent coating with inherent inhibitory effects on neointimal formation in a porcine coronary model. Int. J. Artif. Org., 2002, 25(12), 1166-1173. (Pubitemid 36109103)
54. Lindqvist, U.; Tolmachev, V.; Kairemo, K.; Astrom, G.; Jonsson, E.; Lundqvist, H. Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin. Pharmacokinet, 2002, 41(8), 603-613. (Pubitemid 34848365)
55. Matrosova, V.Y.; Orlovskaya, I.A.; Serobyan, N.; Khaldoyanidi, S.K. Hyaluronic acid facilitates the recovery of hematopoiesis following 5-fluorouracil administration. Stem Cells, 2004, 22(4), 544-555.
56. Lin, R.Y.; Argenta, P.A.; Sullivan, K.M.; Stern, R.; Adzick N.S. Urinary hyaluronic acid is a Wilms' tumor marker. J. Pediatr. Surg., 1995, 30(2), 304-308.
57. Pilarski, L.M.; Pruski, E.; Wizniak, J.; Paine, D.; Seeberger, K.; Mant, M.J.; Brown, C.B.; Belch, A.R. Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells. Blood, 1999, 93(9), 2918-2927.
58. McDonald, B.; McAvoy, E.F.; Lam, F.; Gill, V.; de la Motte, C.; Savani, R.C.; Kubes, P. Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids. J. Exp. Med., 2008, 205(4), 915-927. (Pubitemid 351549887)
59. Thierry, B.; Winnik, F.M.; Merhi, Y.; Tabrizian, M. Nanocoatings onto arteries via layer-by-layer deposition: toward the in vivo repair of damaged blood vessels. J. Am. Chem. Soc., 2003 125(25), 7494-7495. (Pubitemid 36750252)